



FOR IMMEDIATE RELEASE

HAMBURG, 14 AUGUST 2012

United States Patent and Trademark Office Grants Patent on Provecs Medical's Technology

Hamburg | 14 August 2012. Provecs Medical today announces granting of a patent by the United States Patent and Trade Mark office ("US-PTO") covering the technology around Provecs Medical's product Immunalon®. "This US patent marks an important milestone for the creation of value and reinforces Provecs' position in partnering activities with international biotech and pharma partners." comments Frank Schnieders, founder and CEO of Provecs Medical.

Provecs Medical is a privately owned biopharmaceutical company founded in 2007 as a spin-out of the University-Medical Center, Hamburg-Eppendorf in Hamburg, Germany. Provecs Medical specializes in the development of novel targeted immunotherapeutics for cancer and vaccines for infectious diseases based on its ENVIRO technology.

CONTACT

DR. FRANK SCHNIEDERS

PROVECS MEDICAL GMBH
MARTINISTR. 52 – C/O UKE HAUS N30
D-20246 HAMBURG

T +49.40.4126.3268.3
F +49.40.4126.3268.9
schnieders@provecs.com
www.provecs.com